CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS.

被引：0
|
作者：
Zieiba, P. [1 ]
Pawlik, D. [2 ]
Wieczorek, J. [2 ]
Wojcik, R. [2 ]
Kaczor, M. P. [3 ]
机构：
[1] Merck Sp Zoo, Warsaw, Poland
[2] Aestimo Sc, Krakow, MA, Poland
[3] Jagiellonian Univ Med Coll, Krakow, Poland
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND51
引用
收藏
页码：S632 / S632
页数：1
相关论文
共 50 条
  • [1] The cost-effectiveness of disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis
    Bozkaya, Duygu
    Livingston, Terrie
    Migliaccio-Walle, Kristen
    Odom, Tanner
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 297 - 302
  • [2] THE COST-EFFECTIVENESS OF DISEASE MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
    Bozkaya, D.
    Livingston, T. P.
    Migliaccio-Walle, K.
    Mehta, S.
    Odom, T.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : S283 - S283
  • [3] COST-EFFECTIVENESS ANALYSIS OF CLADRIBINE TABLETS FOR TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Dineva, T.
    Panayotov, P.
    Vekov, T.
    [J]. VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [4] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Michels, Renee Else
    de Fransesco, Maria
    Mahajan, Koshu
    Hengstman, Gerald J. D.
    Schiffers, Krijn M. H.
    Budhia, Sangeeta
    Harty, Gerard
    Krol, Marieke
    [J]. APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (06) : 857 - 873
  • [5] Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria de Fransesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    [J]. Applied Health Economics and Health Policy, 2019, 17 : 857 - 873
  • [6] Disease-modifying therapies in relapsing-remitting multiple sclerosis
    Gonzalez-Andrade, Fabricio
    Luis Alcaraz-Alvarez, Jose
    [J]. NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 365 - 373
  • [7] Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis
    Hernandez, Luis
    Guo, Shien
    Toro-Diaz, Hector
    Carroll, Stuart
    Farooq, Syed Feisal Syed
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (03) : 228 - 238
  • [8] Correction to: Cost Effectiveness of Cladribine Tablets for the Treatment of Relapsing-Remitting Multiple Sclerosis in The Netherlands
    Renée Else Michels
    Maria De Francesco
    Koshu Mahajan
    Gerald J. D. Hengstman
    Krijn M. H. Schiffers
    Sangeeta Budhia
    Gerard Harty
    Marieke Krol
    [J]. Applied Health Economics and Health Policy, 2020, 18 : 141 - 141
  • [9] Oral disease-modifying therapies for relapsing-remitting multiple sclerosis
    Thomas, Rachel Hutchins
    Wakefield, Richard A.
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (01) : 25 - 38
  • [10] Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England
    Hettle, Robert
    Harty, Gerard
    Wong, Schiffon L.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (07) : 676 - 686
12345